FDA and NIH Study: Population Assessment of Tobacco and Health
You have saved this web page content. To access this content for publishing, go to My Web Content.
Preview Text for Your Web Page
The following text is a preview of content you can place on your website. After you save it to Your Web Content, we will provide you with a line of code to publish on your website. The text will appear in the style of your website.
The Population Assessment of Tobacco and Health (PATH) Study is a uniquely large, long-term study of tobacco use and health in the United States. A collaboration between the U.S. Food and Drug Administration (FDA) Center for Tobacco Products and the National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA), the study was launched in 2011, started the first wave of data collection in 2013, and is currently in its fourth wave.
On this page:
By following study participants over time, the PATH Study helps scientists learn how and why people start using tobacco, quit using it, and start using it again after they’ve quit, as well as how different tobacco products affect health (such as cardiovascular and respiratory health) over time. Findings from the study may also inform FDA’s actions related to tobacco products, thereby helping to achieve the goals of the Family Smoking Prevention and Tobacco Control Act.
The PATH Study is conducted via a contract awarded to Westat and involves researchers from:
- Center for Tobacco Products, FDA
- National Institute on Drug Abuse, NIH
- Centers for Disease Control and Prevention
- Roswell Park Cancer Institute
- Dartmouth College
- Truth Initiative (formerly Legacy)
- The Medical University of South Carolina
- The University of California, San Diego
- The University of Waterloo
- The University of Minnesota
To learn more, view the “PATH Study 101” video, developed to provide an orientation to the study.
By monitoring and assessing behaviors, attitudes, biomarkers, and health outcomes associated with tobacco use in the United States, the PATH Study helps enhance the evidence base available to inform FDA’s regulatory activities related to tobacco. Specifically, the study aims to:
- Examine what makes people susceptible to using a tobacco product
- Evaluate initiation and use patterns, including the:
- use of newer products, such as e-cigarettes or ENDS (electronic nicotine delivery systems)
- use of multiple products
- switching from one product to another
- Study patterns of tobacco product use, cessation, and relapse
- Track potential behavioral and health impacts, including biomarkers of exposure and harm
- Assess differences in tobacco-related attitudes, behaviors, and health conditions among racial/ethnic, gender, and age subgroups
About 46,000 people aged 12 years and older, including tobacco users and non-users, are included in the first wave of the PATH Study.
Initial data on adult and youth tobacco use, published January 2017 in the New England Journal of Medicine, showed that more than 25 percent of American adults were current users of tobacco in 2013-14 and roughly 9 percent of youth reported using tobacco in the past 30 days. Multiple product use was common among tobacco users, accounting for roughly 40 percent of adult and youth tobacco users, with cigarettes and e-cigarettes being the most common combination among both age groups.
Among tobacco users who reported using more than one product:
- 23 percent of adults and 15 percent of youth used cigarettes and e-cigarettes
- 6 percent of adults and 4 percent of youth used cigarettes and hookah
- 2 percent of adults and 5 percent of youth used e-cigarettes and hookah
- 5 percent of adults and 10 percent of youth used cigarettes and cigarillos
The study reports prevalence for more product combinations used by study participants.
Data and documentation (questionnaires, codebooks) related to the PATH Study are available on the National Addiction & HIV Data Archive Program (NAHDAP) website including: